iShares Nikkei 225 ETF JPY Acc is a equity ETF from iShares tracking the Nikkei 225 index through physical replication. Domiciled in Ireland and launched in 2010, the fund manages about 564 M € and charges a TER of 0.48% — 48 € per year on a €10,000 investment. Income is automatically reinvested in the fund (accumulating).
iShares Nikkei 225 ETF JPY Acc competes with 3 other products on the same index (Nikkei 225): it ranks 2nd by fund size and 4th by ongoing cost, with a TER of 0.48% against a group median of 0.15%. It has been listed since 2010, 16 years of track record — the oldest in its comparison group.
On a €10,000 investment the TER costs 48 € a year. The cheapest of the group is Xtrackers Nikkei 225 (Dist) at 0.09%, or 9 € on the same amount: a difference of 39 € every year, roughly 390 € over ten years before compounding.
Replication is physical: the fund holds the underlying securities directly. The ten largest positions account for 51.5% of the portfolio.
Income is accumulated: no distribution is paid out, the share price absorbs it. In a savings plan this removes the need to reinvest dividends by hand. The fund is denominated in JPY. That is not the same as currency risk: the exposure comes from the currencies of the underlying holdings, not from the denomination or the trading currency of a given listing.
The fund is domiciled in Ireland, which determines the tax treatment of income received by the fund and the supervisory authority.
| Advantest Corp. | 11.1% |
| Tokyo Electron Limited | 11.0% |
| Fast Retailing Co. Ltd. | 9.5% |
| Softbank Group Corp. | 6.8% |
| Kioxia Holdings Corporation | 3.0% |
| TDK Corp | 2.5% |
| Ibiden Co Ltd | 2.3% |
| Fujikura Ltd. | 1.8% |
| Fanuc Corporation | 1.8% |
| Shin-Etsu Chemical Co. Ltd. | 1.7% |
| Borsa Italiana | CSNKY | EUR |
| XETRA | SXRZ | EUR |
| Francoforte | SXRZ | EUR |
| London Stock Exchange | CNKY | GBX |
| SIX Swiss Exchange | CSNKY | JPY |
Source: the fund's KID and the issuer's official documentation — data verified as of July 2026.
This page is informational and is not an investment recommendation. Figures may contain errors or be out of date: always check the KID and the issuer's factsheet before any decision.